Patients with prehypertension who take blood pressure—lowering therapy have a highly statistically significant 22% reduced risk for stroke, a new meta-analysis shows.
The reduction in stroke risk observed in the study was "clear-cut," "clinically meaningful," and evident among all classes of antihypertensive drugs studied, said lead author Ilke Sipahi, MD, assistant professor of medicine, Case Western Reserve University, Cleveland, Ohio, and associate director, Heart Failure and Transplantation at University Hospitals Case Medical Center.
"We saw it with [angiotensin converting enzyme (ACE)] inhibitors, we saw it with calcium channel blockers, and we saw it with angiotensive-receptor blockers [ARBs] to a certain extent," Dr. Sipahi told Medscape Medical News. "So this is true finding: the risk is truly reduced."
However, the study results should not change current recommendations regarding blood pressure—lowering therapy, said Dr. Sipahi. "It's not realistic to go ahead and recommend antihypertensive therapy to every single patient with prehypertensive blood pressure levels, but I think our findings have to be discussed extensively within the medical community.
The study was published online December 8 in Stroke, the Journal of the American Heart Association.
Read more at: http://www.medscape.com/viewarticle/755077?sssdmh=dm1.741070&src=nldne
Source: Medscape Medical News
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen